C. S. Fuchs Et Al. , "Pembrolizumab versus paclitaxel for previously treated patients with PD-L1-positive advanced gastric or gastroesophageal junction cancer (GC): Update from the phase III KEYNOTE-061 trial.," JOURNAL OF CLINICAL ONCOLOGY , vol.38, no.15, 2020
Fuchs, C. S. Et Al. 2020. Pembrolizumab versus paclitaxel for previously treated patients with PD-L1-positive advanced gastric or gastroesophageal junction cancer (GC): Update from the phase III KEYNOTE-061 trial.. JOURNAL OF CLINICAL ONCOLOGY , vol.38, no.15 .
Fuchs, C. S., Ozguroglu, M., Bang, Y., Di Bartolomeo, M., Mandala, M., Ryu, M., ... Fornaro, L.(2020). Pembrolizumab versus paclitaxel for previously treated patients with PD-L1-positive advanced gastric or gastroesophageal junction cancer (GC): Update from the phase III KEYNOTE-061 trial.. JOURNAL OF CLINICAL ONCOLOGY , vol.38, no.15.
Fuchs, Charles Et Al. "Pembrolizumab versus paclitaxel for previously treated patients with PD-L1-positive advanced gastric or gastroesophageal junction cancer (GC): Update from the phase III KEYNOTE-061 trial.," JOURNAL OF CLINICAL ONCOLOGY , vol.38, no.15, 2020
Fuchs, Charles S. Et Al. "Pembrolizumab versus paclitaxel for previously treated patients with PD-L1-positive advanced gastric or gastroesophageal junction cancer (GC): Update from the phase III KEYNOTE-061 trial.." JOURNAL OF CLINICAL ONCOLOGY , vol.38, no.15, 2020
Fuchs, C. S. Et Al. (2020) . "Pembrolizumab versus paclitaxel for previously treated patients with PD-L1-positive advanced gastric or gastroesophageal junction cancer (GC): Update from the phase III KEYNOTE-061 trial.." JOURNAL OF CLINICAL ONCOLOGY , vol.38, no.15.
@article{article, author={Charles S. Fuchs Et Al. }, title={Pembrolizumab versus paclitaxel for previously treated patients with PD-L1-positive advanced gastric or gastroesophageal junction cancer (GC): Update from the phase III KEYNOTE-061 trial.}, journal={JOURNAL OF CLINICAL ONCOLOGY}, year=2020}